Saturday, December 9, 2023

NANOFIBER-BASED GLAUCOMA DRAINAGE IMPLANT (GDI)

 


Synthetic, nanofiber-based GDIs with partially degradable inner cores have been evaluated in a study to assess the effect of surface topography on implant performance.

It was observed in vitro that nanofiber surfaces supported fibroblast integration and quiescence, even in the presence of pro-fibrotic signals, compared to smooth surfaces.



GDIs with a nanofiber architecture were biocompatible, prevented hypotony, and provided a volumetric aqueous outflow comparable to commercially available GDIs.

The authors were of the opinion that that the physical cues provided by the surface of the nanofiber-based GDIs mimic healthy extracellular matrix structure, reducing fibroblast activation and potentially extending functional GDI lifespan. These tubes were also found to minimize conjunctival fibrosis-related gene expression.

Nanofiber-based stents were found to retain architecture and promote cell integration in vivo. This is in comparison to commercially available implants which were found to activate fibrosis within 1-2 months after implantation, in experimental models.

The nanofiber implants were found to reduce subconjunctival fibrosis. Masson's trichrome staining of tissue surrounding smooth GDIs revealed abundant collagen deposition with a capsular thickness of 610±161μm, whereas the subconjunctival space surrounding the 9mm Nano GDIs was edematous with a capsule thickness of 79±45μm (p = 0.0004). this was also confirmed with quantitative analysis of mean fluorescence intensity (MFI) from αSMA stained IF images which showed that the smooth GDI increased fibroblast activation compared to the Nano GDI.

Comparison of nano-tubes, Baerveldt implant and Xen implant


Experimentally cultured fibroblasts on nanofibers were found to have increased levels of IL-33, MMP-10, IL-6, and COL6A6 transcripts which have been associated with successful, non-fibrotic outcomes. Additionally, nanofibers significantly attenuated the expression of the pro-fibrotic marker MYOCD28, 29 under both stimulated and unstimulated conditions.

https://aiche.onlinelibrary.wiley.com/doi/full/10.1002/btm2.10487





No comments:

Post a Comment

LIGHT-ACTIVATED LIPOSOMES FOR GLAUCOMA

  Biomedical researchers at Binghamton University in the USA, have developed a mechanism for drug-carrying liposomes that can be activated i...